- Home
- PBPB vs TNGX Comparison
PBPB vs TNGX Comparison
Compare PBPB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- TNGX
- Stock Information
- Founded
- PBPB 1977
- TNGX 2014
- Country
- PBPB United States
- TNGX United States
- Employees
- PBPB 5000
- TNGX N/A
- Industry
- PBPB Restaurants
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- TNGX Health Care
- Exchange
- PBPB Nasdaq
- TNGX Nasdaq
- Market Cap
- PBPB 278.1M
- TNGX 317.4M
- IPO Year
- PBPB 2013
- TNGX N/A
- Fundamental
- Price
- PBPB $9.32
- TNGX $1.76
- Analyst Decision
- PBPB Strong Buy
- TNGX Strong Buy
- Analyst Count
- PBPB 3
- TNGX 7
- Target Price
- PBPB $15.33
- TNGX $12.33
- AVG Volume (30 Days)
- PBPB 345.9K
- TNGX 801.9K
- Earning Date
- PBPB 03-06-2025
- TNGX 05-07-2025
- Dividend Yield
- PBPB N/A
- TNGX N/A
- EPS Growth
- PBPB 670.59
- TNGX N/A
- EPS
- PBPB 1.31
- TNGX N/A
- Revenue
- PBPB $462,598,000.00
- TNGX $42,069,000.00
- Revenue This Year
- PBPB $5.67
- TNGX N/A
- Revenue Next Year
- PBPB $3.78
- TNGX N/A
- P/E Ratio
- PBPB $7.11
- TNGX N/A
- Revenue Growth
- PBPB N/A
- TNGX 15.17
- 52 Week Low
- PBPB $6.28
- TNGX $1.71
- 52 Week High
- PBPB $13.48
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PBPB 34.02
- TNGX 33.97
- Support Level
- PBPB $8.96
- TNGX $1.80
- Resistance Level
- PBPB $9.64
- TNGX $2.04
- Average True Range (ATR)
- PBPB 0.53
- TNGX 0.18
- MACD
- PBPB -0.14
- TNGX 0.01
- Stochastic Oscillator
- PBPB 13.61
- TNGX 20.19
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.